In the first three months of 2025, Jiangxi Shimei Pharmaceutical has received multiple good news: three new products have been approved for market, two new drugs have been approved for clinical use, and on March 3rd, the new drug clinical application for SMF-217 was submitted...
The company's innovation transformation has entered a new stage. In recent years, the company has actively promoted a differentiated research and development strategy of "first imitation, rush imitation, and high difficulty imitation".
Since 2022, 4 first imitation drugs and 7 new products have been approved, making it one of the top three approved. The rush imitation strength is strong.
Currently, the company has 20 new products under production review, of which 6 will participate in the first imitation competition.
At present, the company's innovative research and development is focused on improving new drugs, with 14 new drugs involving popular fields such as hypertension and depression, which are worth looking forward to.
Next: No More